81.93
0.98 (1.21%)
| Previous Close | 80.95 |
| Open | 80.56 |
| Volume | 234,621 |
| Avg. Volume (3M) | 372,400 |
| Market Cap | 4,058,631,936 |
| Price / Earnings (TTM) | 19.23 |
| Price / Earnings (Forward) | 17.24 |
| Price / Sales | 3.67 |
| Price / Book | 2.27 |
| 52 Weeks Range | |
| Earnings Date | 8 May 2025 |
| Profit Margin | 19.13% |
| Operating Margin (TTM) | 31.68% |
| Diluted EPS (TTM) | 4.26 |
| Quarterly Revenue Growth (YOY) | 2.70% |
| Quarterly Earnings Growth (YOY) | 15.10% |
| Total Debt/Equity (MRQ) | 57.43% |
| Current Ratio (MRQ) | 3.68 |
| Operating Cash Flow (TTM) | 256.57 M |
| Levered Free Cash Flow (TTM) | 191.75 M |
| Return on Assets (TTM) | 6.19% |
| Return on Equity (TTM) | 12.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Prestige Consumer Healthcare In | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.0 |
| Average | 1.38 |
|
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige’s key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer’s Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 1.30% |
| % Held by Institutions | 109.12% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 97.00 (RBC Capital, 18.39%) | Hold |
| Median | 95.00 (15.95%) | |
| Low | 93.00 (Oppenheimer, 13.51%) | Buy |
| Average | 95.00 (15.95%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 84.95 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 21 Mar 2025 | 97.00 (18.39%) | Hold | 84.21 |
| Oppenheimer | 13 Feb 2025 | 93.00 (13.51%) | Buy | 85.68 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 May 2025 | Announcement | Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings |
| 10 Apr 2025 | Announcement | Prestige Consumer Healthcare to Release Fiscal 2025 Fourth Quarter and Year-End Earnings Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |